Page 26 - JCBP-2-3

Journal of Clinical and
Basic Psychosomatics The antidepressant effect of ketamine

doi: 10.2147/JPR.S177098 Neuropsychopharmacol. 2014;17(2):331-336.
72. Park M, Newman LE, Gold PW, et al. Change in cytokine doi: 10.1017/S1461145713001119
levels is not associated with rapid antidepressant response to 82. Woelfer M, Li M, Colic L, et al. Ketamine-induced changes
ketamine in treatment-resistant depression. J Psychiatr Res. in plasma brain-derived neurotrophic factor (BDNF)
2017;84:113-118.
levels are associated with the resting-state functional
doi: 10.1016/j.jpsychires.2016.09.025 connectivity of the prefrontal cortex. World J Biol Psychiatry.
2020;21(9):696-710.
73. Orozco-Solis R, Montellier E, Aguilar-Arnal L, et al.
A circadian genomic signature common to ketamine and doi: 10.1080/15622975.2019.1679391
sleep deprivation in the anterior cingulate cortex. Biol
Psychiatry. 2017;82(5):351-360. 83. Zheng W, Gu L, Zhou Y, et al. Baseline plasma BDNF
levelsare associated with antianhedonic effects of repeated-
doi: 10.1016/j.biopsych.2017.02.1176 dose intravenous ketamine in major depressive disorder.
74. Bellet MM, Vawter MP, Bunney BG, Bunney WE, Sassone- Curr Neuropharmacol. 2023;21(4):1013-1021.
Corsi P. Ketamine influences CLOCK: BMAL1 function doi: 10.2174/1570159X20666220927085706
leading to altered circadian gene expression. PLoS One.
2011;6(8):e23982. 84. Kowalczyk M, Szemraj J, Blizniewska K, et al. An immune
gate of depression - Early neuroimmune development in the
doi: 10.1371/journal.pone.0023982 formation of the underlying depressive disorder. Pharmacol
75. Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic Rep. 2019;71(6):1299-1307.
factor Val66Met polymorphism and antidepressant doi: 10.1016/j.pharep.2019.05.022
efficacy of ketamine in depressed patients. Biol Psychiatry.
2012;72(11):e27-e28. 85. Moaddel R, Shardell M, Khadeer M, et al. Plasma
metabolomic profiling of a ketamine and placebo crossover
doi: 10.1016/j.biopsych.2012.05.031 trial of major depressive disorder and healthy control subjects.
76. Niciu MJ, Iadarola ND, Banerjee D, et al. The antidepressant Psychopharmacology (Berl). 2018;235(10):3017-3030.
efficacy of subanesthetic-dose ketamine does not correlate doi: 10.1007/s00213-018-4992-7
with baseline subcortical volumes in a replication sample
with major depressive disorder. J Psychopharmacol. 86. Kadriu B, Farmer CA, Yuan P, et al. The kynurenine pathway
2017;31(12):1570-1577. and bipolar disorder: Intersection of the monoaminergic
and glutamatergic systems and immune response. Mol
doi: 10.1177/0269881117732514 Psychiatry. 2021;26(8):4085-4095.
77. Ficek J, Zygmunt M, Piechota M, et al. Molecular profile doi: 10.1038/s41380-019-0589-8
of dissociative drug ketamine in relation to its rapid
antidepressant action. BMC Genomics. 2016;17:362. 87. Zhou Y, Zheng W, Liu W, et al. Antidepressant effect of
repeated ketamine administration on kynurenine pathway
doi: 10.1186/s12864-016-2713-3 metabolites in patients with unipolar and bipolar depression.
78. ACNP 58 Annual Meeting: Poster Session II. Brain Behav Immun. 2018;74:205-212.
th
Neuropsychopharmacology. 2019;44(Suppl 1):230-384. doi: 10.1016/j.bbi.2018.09.007
doi: 10.1038/s41386-019-0546-x 88. Chen MH, Bai YM, Wu HJ, et al. Role of klotho on
79. Zarate CA Jr., Brutsche N, Laje G, et al. Relationship of antidepressant and antisuicidal effects of low-dose ketamine
ketamine’s plasma metabolites with response, diagnosis, infusion among patients with treatment-resistant depression
and side effects in major depression. Biol Psychiatry. and suicidal ideation. J Affect Disord. 2023;340:471-475.
2012;72(4):331-338. doi: 10.1016/j.jad.2023.08.061
doi: 10.1016/j.biopsych.2012.03.004 89. Chen MH, Lin WC, Li CT, et al. Effects of low-dose ketamine
80. Beanes G, Caliman-Fontes AT, Souza-Marques B, et al. Effects of infusion on vascular endothelial growth factor and matrix
GRIN2B, GRIA1, and BDNF polymorphisms on the therapeutic metalloproteinase-9 among patients with treatment-
action of ketamine and esketamine in treatment-resistant resistant depression and suicidal ideation. J Psychiatr Res.
depression patients: Secondary analysis from a randomized 2023;165:91-95.
clinical trial. Clin Neuropharmacol. 2022;45(6):151-156. doi: 10.1016/j.jpsychires.2023.07.022
doi: 10.1097/WNF.0000000000000517
90. Huang C, Wu Z, Wang D, et al. Myelin-associated
81. Haile CN, Murrough JW, Iosifescu DV, et al. Plasma oligodendrocytic basic protein-dependent myelin repair
brain derived neurotrophic factor (BDNF) and response confers the long-lasting antidepressant effect of ketamine.
to ketamine in treatment-resistant depression. Int J Mol Psychiatry. 2023.

Volume 2 Issue 3 (2024) 13 doi: 10.36922/jcbp.2596